Axogen, Inc. (AXGN)
- Sector
- Healthcare
- Industry
- Medical Devices
- Last price
- $49.25
- As of
Kresmion compiles this page from AXGN's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Axogen, Inc. (AXGN): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-10-28.
See the full AXGN dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for AXGN on one page. Preview it with sample data, then open it live with a free account.
Preview the AXGN dossierActive events for AXGN
- high13F: funds reduced
3 tracked funds reduced AXGN this 2026Q2, institutional consensus
- high13F: large reduction
CITADEL ADVISORS LLC cut 95% of AXGN (2026Q2)
- high13F: large reduction
CITADEL ADVISORS LLC cut 94% of AXGN (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +815% to AXGN (2026Q2)
- high13F: large reduction
MILLENNIUM MANAGEMENT LLC cut 97% of AXGN (2026Q2)
FREE, NO ACCOUNT
Every event on AXGN, as it fires
You are seeing 5 of 13 events recorded on AXGN since 2026-05-16.
The five above all landed on 2026-08-16. The other 8 were recorded on 2 other days. 8 of the 13 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in AXGN (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 05463X106 · 2026Q2 | $62.9M | 0.01% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 05463X106 · 2026Q2 | $14.7M | 0.01% | , |
| D. E. Shaw & Co., Inc.CUSIP 05463X106 · 2026Q2 | $12.8M | 0.01% | , |
| Point72 Asset Management, L.P.CUSIP 05463X106 · 2026Q2 | $10.4M | 0.01% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 05463X106 · 2026Q2 | $1.3M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, AXGN
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
AXGN against its peers
AXGN's operating margin of -3.5% ranks in the 57th percentile of 21 Medical Devices sub-industry peers, fiscal periods ending between 2025-12-28 and 2026-05-31.
| Metric | AXGN | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 225M USD | 370M USD | 39 | 21 |
| Gross margin | 74.3% | 62.1% | 74 | 20 |
| Operating margin | -3.5% | -11.1% | 57 | 21 |
| Net margin | -7.0% | -9.4% | 52 | 21 |
| Return on equity | -12.2% | -9.4% | 39 | 21 |
| P / E | n/a | 29.2x | n/a | 7 |
Peers (21): NEOG, UFPT, BFLY, ESTA, ENOV, AVNS.D, AORT, CBLL, BBNX, SIBN, QDEL, IART, BIO, INMD, GMED, SNN, KIDS, TCMD, DCTH, SSII, MASS. Left out: ALMR (no annual filing), OSSUY (no annual filing), NHNKF (no annual filing), LMRI (no annual filing). Fiscal periods ending between 2025-12-28 and 2026-05-31. Every figure is one full fiscal year read from one annual filing (AXGN: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow AXGN on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to AXGN for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.